Date: 2016-10-07
Type of information: Collaboration agreement
Compound: National Cancer Institute's Blood Profiling Atlas
Company: Eli Lilly (USA - IN) National Cancer Institute (NCI) (USA)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
- database. The Blood Profiling Atlas is part of the Cancer Moonshot initiative. A pilot was launched on October 17, 2016 to accelerate the development and validation of liquid biopsy assays to improve the outcomes of patients with cancer. The pilot will be curated by a partnership between the University of Chicago and Seven Bridges, a biomedical data analysis company.
- This open database will feature raw data sets from circulating tumor cells, circulating tumor DNA, and exosome assays, as well as relevant clinical data, sample preparation, and handling protocols from 12 different studies.
Disease:
Details:
- • On October 17, 2016, Eli Lilly announced it will contribute cancer research data to the National Cancer Institute's Blood Profiling Atlas, an open access liquid biopsy database being created in response to Vice President Joe Biden's call to action and in alignment with the goals of the Cancer Moonshot initiative. The database is an effort to reduce the development time of effective and safe blood profiling diagnostic technologies.
- In support of this overarching mission, Lilly is studying approaches for the profiling of exosomes for mRNA and non-coding RNA expression and will share sample preparation methods, next-generation quantitative PCR-based methods, and next generation sequencing-based methods along with data related to disease characterization through gene expression analysis.
Financial terms:
Latest news:
Is general: Yes
